ABOUT US
SonoNeu is a biotechnology company pioneering the development of sonogenetics, an emerging modality that uses ultrasound to precisely and non-invasively control specific cells engineered with ultrasound-responsive proteins. A spin-out from the Salk Institute and co-founded by General Inception, SonoNeu was created by neuroscientist Sreekanth Chalasani, PhD, whose foundational research established sonogenetics as a new approach to modulating cellular activity.
The company is translating sonogenetics into drug-free therapies, which can be switched “on” and “off” when needed, and targeted exactly where needed. The with a long-term vision is to enable non-invasive treatments across a broad range of disorders.
THE TECHNOLOGY
Sonogenetics: A New Paradigm
SonoNeu combines engineered ultrasound-sensitive proteins with focused ultrasound delivery to achieve precise, programmable cellular control.
Sonochannel Targeting
Focused Ultrasound Stimulation
Precise Cellular Control
THE TEAM
Sreekanth Chalasani, PhD
Co-Founder
Professor at the Salk Institute for Biological Sciences, a pioneer in sonogenetics research
Venkat Reddy, PhD
Co-Founder
Chief Scientific Officer of General Inception
Sara Jones, PhD
Scientific Advisor
VP, Science and Technology at General Inception
INVESTORS & INSTITUTIONAL SUPPORT
Contact Us
For inquiries, please reach out to our team.